Stress, Diurnal Cortisol, and Breast Cancer Survival
This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
First received: September 13, 2005
Last updated: November 9, 2012
Last verified: November 2012
The purpose of this study is to learn about the effects of stress on hormones, the relationship between these hormones and cancer progression.
||Observational Model: Cohort
Time Perspective: Prospective
||Stress, Diurnal Cortisol, and Breast Cancer Survival
Biospecimen Retention: Samples Without DNA
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Primary Completion Date:
||November 2004 (Final data collection date for primary outcome measure)
Calculated per patient
The purpose of this study is to investigate stress and tonic activation of diurnal cortisol in aging metastatic breast cancer patients; feedback inhibition & activation of cortisol; and stress-induced phasic activation of cortisol.
|Ages Eligible for Study:
||35 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
patients with recurrent or metastatic breast cancer
- Diagnosis of recurrent or metastatic breast cancer.
- Karnofsky of 70% or greater.
- Proficient enough in English to be able to take questionnaires and participate in the required tasks.
- Living within the Greater Bay Area.
- Age 35 or older .
- Positive supraclavicular lymph nodes as the only metastatic lesion at the time of initial diagnosis.
- Active cancers within the past 10 years other than breast cancer, basal cell or squamous cell carcinomas of the skin, or in situ cancer of the cervix.
- Any other serious medical condition that will effect short term survival
- History of major psychiatric illness for which patient was hospitalized or medicated, with the exception of depression or anxiety
- A diagnosis of diabetes.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00226967
|Stanford University School of Medicine
|Stanford, California, United States, 94305 |
No publications provided
History of Changes
|Other Study ID Numbers:
||BRSADJ0006, 76389, BRSADJ0006, 12273
|Study First Received:
||September 13, 2005
||November 9, 2012
||United States: Food and Drug Administration
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 18, 2014
Neoplasms by Site